Edition:
India

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

1.85USD
19 Jan 2018
Change (% chg)

$0.01 (+0.54%)
Prev Close
$1.84
Open
$1.86
Day's High
$1.86
Day's Low
$1.83
Volume
12,234
Avg. Vol
30,958
52-wk High
$3.72
52-wk Low
$1.53

Select another date:

Fri, Jan 5 2018

BRIEF-Scynexis Provides Corporate And SCY-078 Pipeline Update

* SCYNEXIS INC - ‍INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078​

BRIEF-Scynexis reports third quarter 2017 financial results

* Scynexis reports third quarter 2017 financial results and provides company update

BRIEF-Scynexis presents new data related to SCY-078​

* Scynexis Inc - ‍data demonstrates broad activity and potential clinical utility of SCY-078 against invasive candida and aspergillus infections Source text for Eikon: Further company coverage:

BRIEF-Scynexis CEO Marco Taglietti​ buys 10,000 shares of co's common stock on Aug 15

* Scynexis Inc CEO‍ Marco Taglietti​ reports purchase of 10,000 shares of co's common stock on Aug 15 at $1.61 per share - SEC filing Source text: (http://bit.ly/2wj4Cck) Further company coverage:

BRIEF-Scynexis Q2 loss per share $0.16

* Scynexis reports second quarter 2017 financial results and provides company update

BRIEF-SCYNEXIS announces initiation of dosing in Phase 2 study evaluating oral SCY-078 in Vulvovaginal Candidiasis

* SCYNEXIS announces initiation of dosing in Phase 2 study evaluating oral SCY-078 in Vulvovaginal Candidiasis

Select another date: